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Abstract
Purpose Autoimmune retinopathies and optic neuropathies
are complex disorders of the retina and the optic nerve, in
whichpatients developautoantibodies (AAbs)againstretinal
and optic nerve proteins. Autoimmunity might significantly
influence theoutcomeofretinalandopticnerve degenerative
process but the pathogenic process is not fully elucidated. To
better understand the role of AAbs in pathogenicity of these
suspected autoimmune visual disorders, we focused on
unique AAbs specificities associated with the syndrome to
identify their antigenic targets in the optic nerve and retina.
Methods Serum samples were obtained from patients,
whose visual disorders were potentially autoimmune in
nature, including patients with cancer with possible para-
neoplastic syndrome. Autoantibodies were tested against
human optic nerve and retinal antigens for specificity by
Western blotting and immunofluorescence.
Results Out of 209 tested for anti-optic nerve autoanti-
bodies, 55% showed specific neuronal autoantibodies. The
repertoire of anti-optic nerve autoantibodies often differed
from anti-retinal antibodies. The major antigenic targets for
these antibodies could be divided into four groups.
Autoantibodies specific to classical glycolytic enzymes
involved in energy production (α and γ enolases, glycer-
aldehyde 3-phosphate dehydrogenase) also reacted with
retinal antigens. Autoantibodies targeted neuronal-specific
myelin proteins (MBP , MOG), aquaporin 4, and collapsing
response mediator protein 5 reacted with optic nerve
antigens. They showed immunostaining of axons and
myelin in the optic nerve as determined by double
immunofluorescence.
Conclusion We identified novel neuronal autoantigens not
previously known to be associated with acquired autoim-
mune retinopathy and optic neuropathy. Knowledge of the
full autoantibody repertoire perpetuating this syndrome is
an important first requirement in increasing our understand-
ing of the autoimmune process to facilitate better diagnosis,
prognosis, and treatment.
Keywords Autoimmunity.Retinopathy.Optic nerve.
Neuropathy.Autoantibodies.Retina.Immunofluorescence.
Western blotting.Retinal degeneration
Introduction
Presence of autoantibodies (AAbs) specific against antigens
present in the retina is the hallmark of autoimmune process
in cancer-associated retinopathy (CAR) and autoimmune
retinopathy (AR) [1, 2]. Patients diagnosed with paraneo-
plastic or non-paraneoplastic retinopathy often present with
optic nerve problems not related to glaucoma. Serum anti-
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variety of neurological disorders but anti-optic nerve AAbs
has not been extensively studied. Autoimmune retinopathies
and optic neuropathiesare complex disorders ofthe retinaand
the optic nerve, in which patients develop AAbs against
retinalandopticnerveproteins[3]. Dependent on whether the
syndrome is targeting the retina, optic nerve, or both, the
pathogenesis of these syndromes are poorly elucidated and
may be characterized by progressive loss of visual acuity
and/or visual field sensitivity, loss photoreceptors and/or
retinal ganglion cells (RGCs) and their axons, and optic
nerve head changes, such as pallor, hyperemia, edema,
swelling, or dropout of the retinal nerve fiber layer (RNFL)
by optic coherence tomography (OCT) imaging [4–8].
Thus far, most studies have focused on AAbs in glaucoma
and neuronal loss due to the loss of RGCs [9, 10]. The
perceived pathology of autoimmune optic neuropathy and
glaucoma is different, although both might have a similar
underlying autoimmune cause [6, 11]. It is important to point
out that the immune response might significantly influence
the outcome of retinal and optic nerve degenerative process.
For example, AAbs can exert their pathogenic effects if they
gain access from the periphery to the central nervous system
(CNS)/eye when the integrity of the blood barriers is
compromised. Because there is little known about pathoge-
nicity of retinopathy and associated optic neuropathy, we
undertook a first line of investigation focusing on unique
AAbs specificities associated with the syndrome that is
thought to be autoimmune in nature, including patients with
cancer with potential paraneoplastic syndrome. These
patients had symptoms of optic nerve and/or retinal
dysfunction, some of which have been found to have
electrophysiological evidence of retinal process, or other
findings to suggest an optic nerve process. However, work-
up did not reveal a definite known disorder. In this patient
population, we found autoantibodies that target antigens
present in the optic nerve and retina, may affect the outcome
of the visual dysfunction. The identity of antigenic targets
that those AAbs recognize in the optic nerve will allow for a
better understanding of the molecular mechanism of RNFL
and axonal loss during optic neuropathies. Our study shows
that these patients have unique AAbs against neuronal
antigens often different from the retinal antigens.
Materials and methods
Patients
Patient's sera were acquired through the Ocular Immunol-
ogy Laboratory through retrospective serological evaluation
for anti-retinal autoantibodies. The study has been approved
by the OHSU Institutional Review Board.
Western blotting
Human retinal proteins were extracted from the retina or
optic nerve with 2% octyl glucoside in phosphate buffer,
pH 7.2 and 10-μg protein was used for electrophoresis
using Bio-Rad Criterion gels following by transfer to PVDF
membrane [2]. As positive controls, we used monoclonal
antibodies against α-enolase and γ-enolase diluted 1:2,000.
A negative control contained secondary antibodies only.
The reactivity with a suspected known protein was
confirmed by an additional Western blotting using an
appropriate purified protein. Also, we used brain extract
prepared by the same method as was used to extract retinal
proteins to confirm reactivity with neuronal antigens.
Fluorescent immunohistochemistry
Rat eye posterior globe containing the whole retina and optic
nerve was fixed in 4% paraformaldehyde for 1 h followed by
30% sucrose infiltration overnight and the globe was frozen in
Tissue-Tek optimal cutting temperature compound. Ten-
micron cryosections were prepared for incubation with human
serum. Briefly, sections were blocked with 10% normal goat
serum with 1% bovine serum albumin for 60 min followed by
incubation with patient's serum overnight. After washing,
fluorescent anti-human IgG labeled with FITC or biotin-
labeled anti-human IgG followed by Texas Red labeled to
streptavidin were added for 1 h. The mounting reagent, which
inhibited fluorescence quenching and contained DAPI for
nuclear staining was used to seal the sections. The labeling
was evaluated in a Leica DM5000 fluorescent microscope
and pseudocolor images were acquired for analysis. A
negative control contained secondary antibodies only.
For double staining we used biotinylated anti-human
IgG followed by Streptavidin conjugated to Texas Red or
antibodies specific to cell markers at 1:100 dilutions:
neuronal fibers (RT97) (Chemicon), glial fibrillary acidic
protein (GFAP) (BD Pharmingen) for astrocytes and cyclic
nucleotide phosphodiesterase (CNPase) (Thermo Scientific)
and myelin oligodendrocyte glycoprotein (MOG) (Abnova)
for oligodendrocytes followed by the appropriated second-
ary antibodies conjugated to Alexa Fluor 488. After
incubation with antibodies, tissue sections were washed
and mounted with DAPI. The acquired images were merged
using Photoshop software to show specific cellular labeling.
Results
General characteristics of patients
Our cohort of 209 patients presented painless and progres-
sive, most commonly acute or subacute visual loss, loss of
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changes on ophthalmoscopy, usually decreased retinal
function on electroretinigraphy (ERG), delayed visual
evoked potentials (VEPs), in some thinning of the retina
and RNFL changes on OCT imaging, and showed the
presence of serum antibodies against optic nerve proteins in
addition to anti-retinal AAbs. Optic nerve head changes,
including: marked hyperemic swelling; RNFL thickening,
thinning, or both; disc pallor;, cupping of the optic nerve
head; and/or frank optic nerve atrophy was reported in 51
patients. Of the 209 patients with average age 55 years old
(ranged from 18 to 88 years old), 116 patients (55.5%) had
AAbs against retinal and optic nerve antigens (Fig. 1a). The
ratio of male to female was almost equal (1:1.5). Sixty nine
of 116 patients (42 women and 27 men) of average age
61.5 years old had different types of cancer. The most
common cancers associated with the syndrome were breast
cancers (13 patients) and melanomas (11 patients) (Fig. 1b).
Thirty eight out 69 paraneoplastic patients had AAbs
against optic nerve proteins that often differed in specificity
from anti-retinal proteins and targeted autoantigens specific
for the optic nerve. Table 1 shows AAb testing results from
30 paraneoplastic patients with systemic cancers; 7 patients
with intraocular cancer were not included in the table.
Since the presence of AAbs against optic nerve antigens
has not been previously tested in healthy individuals, we
also analyzed 56 normal sera (32 females of average age
47 years and 24 males of average age 45 years) for anti-
optic nerve AAbs by Western blotting. The vast majority of
normal sera, showed no or low reactivity with optic nerve
proteins. Only four out of 56 sera (7%) weekly reacted with
optic nerve proteins (35, 46, 62 kDa) as determined by
Western blotting (not shown).
Anti-optic nerve autoantibodies
Initially, the patients' sera were tested for anti-retinal and
anti-optic nerve autoantibodies by Western blotting and we
found that antibodies against both tissue antigens coexist in
the serum (Fig. 2). In this study, we focused on identifica-
tion of optic nerve autoantigens that immunoreacted with
serum AAbs. The highest number of serum AAbs (23
patients) bound to enzymatic proteins, including both α and
γ (or NSE, neuron specific enolase) enolases (46 kDa). In
addition, patient AAbs frequently targeted retinal and optic
nerve antigen of apparent molecular weight of 36 kDa that
was further analyzed for molecular identify by immuno-
precipitation. This new antigen was identified by MS/MS
analysis as glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), also a glycolytic enzyme that converts glycer-
aldehyde 3-phosphate to D-glycerate 1,3-bisphosphate.
Figure 3 shows reactivity of 18 different sera with purified
human GAPDH protein on the blot. Some patients
recognized another glycolytic enzyme, aldolase. Forty sera
had antibodies that recognized low molecular weight
proteins associated with CNS myelin such as myelin basic
protein (MBP , 33 kDa), MOG (28 kDa) or proteolipid
protein, PLP (30 kDa). These anti-neuronal antibodies
bound to the optic nerve and brain proteins but not to
retinal antigens, which is in agreement with the unique
localization of those myelin proteins in CNS tissues,
including optic nerve (not shown). Also, several patients
reacted with 62-kDa protein that had the same molecular
weight as collapsin response-mediated protein 5 (CRMP5).
Previously published studies showed anti-CRMP5 anti-
bodies were associated with paraneoplastic optic neuritis
[12]. Four patients reacted with 40-kDa optic nerve protein,
Fig. 1 Demographics of 209 patients with autoimmune retinopathy and autoimmune optic neuropathy in the study: a Seropositive patients with
anti-optic nerve autoantibodies in patients with cancer and without cancer. b Distribution of cancers in 69 patients with paraneoplastic syndromes
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Number Sex Age Diagnosed cancer Onset
of
cancer
Onset of
visual
symptoms
Reported optic nerve
findings
Anti-optic nerve
AAbs
Anti-retinal
AAbs
1 F 43 Brain venous
angioma
2006 2004 46 k 46 k
2 F 43 Breast Apparent temporal
pallor
27 k, 35 k 27 k
3 F 50 Breast 2005 2007 Bilateral temporal
optic disc pallor
and juxtapapillary
atrophic changes
OD>OS
46 k 46 k
4 F 59 Breast 1999 2006 Glaucoma 24 k,36 k, 50 k,
70 k
46 k, 62 k, 70 k,
112 k
5 F 55 Breast Optic neuropathy 46 k, 82 k 46, 66 k, 82 k
6 F 68 Breast Sequential episodes
of optic neuropathies
30, 42 k low negative
7 F 58 Breast 23 k, 27 k 23 k, 25 k, 32 k, 33 k
8 F 60 Breast 2008 62 k 35 k,38 k low
9 F 47 Breast metastatic
to brain
Congenital optic nerve
change with tilting OS,
30 k, 36 k 46 k
10 F 56 Cervix 1983 2009 Slightly enlarged cup
to disc ratio bilaterally
36 k, 42 k, 96 k 30 k
11 F 58 Cervix 46 k
12 M 64 Colorectal 2004 2008 23 k 40 k, 44 k, 46 k, 60 k
13 F 71 Endometrium
metastatic
46 k 46 k high
14 F 61 Glioblastoma Homonymous
hemianopsia
OD, hemi between the
macula and optic nerve
35 k low 35 k low
15 M 43 Malignant
hepatoma
2006 2005? Optic atrophy 33 k 33 k
16 F 65 Lung 2008 2006 7 proteins 35–50 k 28 k, 46 k
17 F 78 Lung non-small
cell carcinoma
Holes in both capsules 30 k 30 k
18 F 55 Lymphoma CNS 2006 70 k 70 k
19 F 83 Melanoma Optic neuropathy 28 k 47 k, 70 k, 112 k
20 F 79 Melanoma 46 k, 45 k 46 k
21 M 61 Melanoma 30 k 30 k
22 F 72 Ovarian 46 k 35 k, 46 k
23 M 77 Prostate 1996 2003 RNFL slightly thinned
temporally OD;
61 k, 62 k 30 k, 67 k, 112 k
24 M 79 Prostate 2005 2000 41 k negative
25 M 85 Prostate and
adrenal adenoma
2002 24–25 k negative
26 M 77 Prostate and skin
cancers
2001 2005 24–26 k negative
27 F 61 Rectal 2008 2003 V ery enlarged blind
spots OU
46 k 46 k
28 F 35 Renal ~2008 46 k 30 k, 46 k, 90 k,
140 k
29 F 70 Thyroid 2006 V ertical optic nerve head
cupping OS>OD, in
OS with peripapillary
atrophy
90 k 49–50 k, 90 k
30 M 72 Thyroid benign 2004 ~1973 36 k, 54 k 27 k, 30 k, 33 k
k kilodaltons; OS left eye, OD right eye
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aquaporin 4 (AQP4), a water channel protein usually
associated with neuromyelitis optica [13].
Astrocytic and neuronal immunoreactivity in the optic
nerve
To further confirm the immunoreactivity with optic nerve
proteins and to identify cellular targets for these seropos-
itive AAbs in relation to autoimmune optic neuropathy, we
carried out a series of double-immunofluorescent labeling
studies using rat optic nerve thin cryosections. The patients'
sera were co-incubated with specific antibodies against
astrocytes (GAFP), neuronal fibers (RT97), and oligoden-
drocytes (CNPase and MOG), aquaporin 4 (AQP4), NSE,
and CRMP-5 in double-staining experiments. No
oligodendrocyte-specific labeling was detected in the retina
(not shown). GFAP immunolabeled the RGC layer and RT-
97 labeled the neuronal axons of the normal rat retina. All
those antigens were present in the optic nerve. No staining
was observed with control sera whereas groups of seropos-
itive sera showed similar labeling patterns.
Surprisingly, seropositive AAbs tested revealed strong
immunolabeling of the optic nerve. Most sera labeled the
optic nerve in two different patterns—they showed
axonal or glial staining. Figure 4 shows an immunolabel-
ing of axonal fibers (A–C) and glial columns (D–E) by
representative sera in a similar pattern to that of specific
marker antibodies for those cellular structures such as
axonal staining with RT97 antibodies and glial staining by
anti-GFAP antibodies, respectively. The labeling of astro-
cytes in the RGC layer and optic nerve confirmed by
GFAP co-labeling implies that these AAbs recognize
antigens located in astrocytes. For instance, as shown in
Fig. 5, strong immunolabeling of astrocytes was present
(Fig. 5b,c) on cross- and transverse sections of the optic
Fig. 2 Western blot analysis of autoantibodies against optic nerve
present in patients in the studies: a Bar graph showing a percent of
patients' sera reacting with the following autoantigens: Enolase,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), myelin basic
protein (MBP), oligodendrocyte-myelin glycoprotein (MOG), or
proteolipid protein (PLP), CRMP-5, aquaporin-4 (AQP4), Tubulin,
and other unidentified autoantigens in the optic nerve. b.A
representative blot for nine patients, two positive controls marked by
(positive sign) correspond to neuron specific enolase, and α-enolase;
(negative sign) negative control, no patient's serum
Fig. 3 Immunoreactivity of 18
representative patients' sera and
control specific antibodies
with 1-μg purified human
GAPDH proteins was
loaded on the blot
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proteins of molecular weight 30 and 36 kDa (GAPDH) on
the blot. We observe that number of sera-labeled RGC
axon bundles in the nerve fiber layer, the lamina cribrosa,
and the retrobulbar optic nerve. A representative double-
immunofluorescent labeling for patient's serum and RT97
antibodies, an axonal marker, confirmed the AAbs spec-
ificity for neuronal axons (Fig. 6). AAbs-positively
immunolabeled cell processe so r g a n i z e di nl o n gt r a i l si n
the optic nerve (asterisks).
The different immunolabeling pattern is represented by
the strong staining of cell bodies and their dendrites in the
optic nerve. Figure 7 shows representative pictures for two
patient's sera that have AAbs against an optic nerve 42-kDa
protein. In the retina, these AAbs labeled RGCs and cells in
the inner nuclear layer (Fig. 7a, d). The optic nerve cellular
labeling strongly suggested their binding to oligodendro-
cytes (Fig. 7b, e). Consequently, we double labeled the
optic nerve with patient's serum and anti-MOG antibodies
as marker for oligodendrocytes. As it can be seen on the
transverse ON sections, the patients' AAbs bound to
oligodendrocyte cell membranes and processes in the same
manner as did anti-MOG antibodies (strong yellow color on
double-labeling experiment in Fig. 7c, f), confirming
specificity of antibodies to myelin protein.
The presence of AAbs in the patients' sera against 62-
kDa protein suggested reactivity with CRMP-5 protein.
Double immunofluorescence of the optic nerve showed that
anti-62-kDa-specific sera labeled oligodendrocyte soma
(cytoplasm) and processes close to myelin in a similar
Fig. 4 Immunolabeling patterns by patients' autoantibodies on the
longitudinal sections of the rat optic nerve. Representative immuno-
fluorescent labeling for 3(a, b, c) sera shows labeling of axons similar
to that of the axonal marker RT97 (d) indicated by asterisks (top
pictures). Bottom pictures show other three representative sera (e, f, g)
that labeled astrocytic columns (arrows) in the optic nerve in a similar
pattern to that of the astrocyte marker GFAP (h); green FITC for
antibodies; blue DAPI for nuclei
Fig. 5 Double-immunofluorescent labeling in the rat retina (a) and
optic nerve (b, c) with anti-GFAP antibodies as marker for astrocytes
showing that patient's autoantibodies are predominantly anti-astrocytic
(asterisks and arrows) : serum (red), GFAP (green), and colocalization
(yellow), nuclear labeling with DAPI (blue); ON optic nerve
116 J Ophthal Inflamm Infect (2011) 1:111–121Fig. 6 Double-immunofluorescent labeling patient's autoantibodies
showing labeling of neuronal axons in the retina (a) and transverse (b)
and cross section of optic nerve (c). serum (red), RT97 (green), and
colocalization in c (yellow); nuclear labeling with DAPI (blue). Note
that axons were compartmentalized into distinct bundles (circled in c)
Fig. 7 Immunofluorescent label-
ing of the retina and optic nerve
with two representative patients
sera that labeled cells in ganglion
and inner nuclear layer in the
retina (a, d) but oligodendrocytes
in the optic nerve (b, e; arrows);
in double-immunofluorescence
labeling autoantibody immuno-
reactivity overlapped with anti-
MOG antibodies, a marker
for oligodendrocytes (c, e);
serum (red), MOG (green), and
colocalization (yellow), nuclear
labeling with DAPI (blue)
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Other AAbs immunolabeled astrocytes and showed a
distinct punctate immunoreactivity on the cell surface and
blood vessels (Fig. 8c–e) indicative of AQP4 labeling.
AQP4 is expressed on astrocytes. In double-staining
experiments, we co-localized three patients' sera with anti-
AQP4 antibodies in the optic nerve (yellow merged color).
A number of sera recognized NSE when incubated with
optic nerve proteins on the blot and those sera stained
predominantly the cytoplasm of oligodendrocytes in the
tissue (Fig. 8f, g).
Discussion
Autoimmunity to retinal, neuronal, and axonal antigens
may play a role in inducing cellular degeneration. The
specific AAbs against retinal antigens are most commonly
associated with CAR and AR but their pathogenic effects
were not fully established [14]. The current studies showed
that serum anti-optic nerve AAbs are also present in more
than 50% patients tested in patients with either CAR or AR.
The major optic nerve antigenic targets for patients AAbs
described in these studies can be divided into four
categories as follows: (1) classical glycolytic enzymes
involved in energy production, including α and γ enolases,
glyceraldehyde 3-phosphate dehydrogenase, which also
reacted with retinal antigens; (2) neuronal-specific myelin
proteins; (3) CRMP5; (4) AQP4. Also other antibodies
were present but their antigens have not yet been
discovered and are under investigation. The newly identi-
fied AAbs labeled optic nerve components such as axons,
astrocytes, and oligodendrocytes. Although their role in the
pathogenicity of the optic neuropathy affecting these
patients needs to be evaluated further, we believe that these
unique anti-optic nerve AAbs can be valuable disease
markers. We observed that the AAb presence correlated
with various clinical (ophthalmoscopic changes at or
around the disc), imaging (thinning or, in fact, swollen
RNFL), and functional findings presented by affected
patients, not usually seen in retinopathies. Moreover,
distinct autoantigens may become novel therapeutic targets
in disease, e.g., blocking GAPDH-mediated cell death in
pathological conditions. Therefore, the identity of cellular
targets is important in better understanding the etiology of
autoimmune retinopathy associated with optic neuropathies,
whether with or without retinopathy, and for developing
better treatments. Our research was solely intended to
identity of anti-optic nerve AAbs targets because this area
was not explored before. The future studies will evaluate
their responsiveness to immunosuppressive treatments for
neuro-retinopathy targeting reducing the antibody titers on
follow-up testing and clinical response to therapy.
The definition of the autoimmune neuro-retinopathy is
not well defined. Autoimmune optic neuropathy (AON)
was first described by Dutton et al. as recurrent episodes of
optic neuropathy with AAbs but as a different entity distinct
from demyelinating optic neuritis [15]. In general, AON
has been characterized by chronically progressive or
recurrent visual loss associated with serological evidence
of autoimmunity and without a defined systemic autoim-
mune disorder [4]. Later, autoimmune-related retinopathy
and optic neuropathy (ARRON) has been defined by the
Keltner’s group as a syndrome that is characterized by
visual loss and often the presence of antibodies against
retinal or optic nerve antigens in the absence of cancer [16].
Fig. 8 Representative patient's sera immunoreactivity with the optic
nerve. Longitudinal section of the rat optic nerve double-labeled
representative patients' sera (green) and one of the following control
antibodies: a, b with anti-CRMP-5 (red), c–e anti-APQ4 (red) and f, g
anti-NSE antibodies (red); colocalization (yellow) and nuclear labeling
with DAPI (blue); arrowheads point at the reactive cellular structures
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more than half had both anti-retinal and anti-optic nerve
autoantibodies, and third of them has been diagnosed
with cancer at the time of testing for antibodies. We
recommend the following unique measurements that help
improve the diagnosis for optic neuropathy in the context
of retinopathy: delay VEPs, pattern of visual fields loss
that is not clearly consistent with retinopathy, attenuated
and/or thickened RNFL as measured by OCT imaging
criteria, compromised photopic negative response
(PhNR) of the photopic flash ERG, which is mediated
by RGCs, and the presence of AAbs, some of which may
label RGCs in the tissue. Our research identified new
AAbs specific against optic nerve antigens not previously
known in autoimmune neuropathy associated with reti-
nopathy, suggesting the autoimmune nature of the
syndrome also at the optic nerve level. If pathogenic,
A A b sb i n d i n gt op r o t e i n si no p t i cn e r v en e u r o n sm a y
lead to disruption of protein function, apoptosis of cells,
as well as inhibiting enzymes that preserve neuronal
glycolytic activity and neuronal integrity.
A high prevalence of various AAbs in patients with
neuro-retinopathy suggests a polyclonal activation of the
humoral immune system. It is not clear what the role of
each AAb is in autoimmune optic neuropathy and whether
the AAbs contribute to pathogenicity at all. We hypothesize
that autoimmune damage to the retina and optic nerve may
be caused directly by the AAbs, or indirectly by a non-
immune cause that contributes to tissues damage but may
activate the secondary immune responses as a result of
neuronal degeneration. During pathogenic processes, AAbs
could bind to neuronal proteins in optic nerve and retina,
inhibiting enzymes that preserve neuronal glycolytic activ-
ity and neuronal integrity, which may ultimately lead to
apoptosis of those cells [17]. Thus, AAbs may be directly
involved in the induction of pathogenic processes or could
be related to the progression over time of ongoing
pathological processes in the retina and optic nerve. In the
latter, specific AAbs related to specific phenotype could be
considered as biomarkers related to disease. We identified
AAbs that belong to the group of neuronal glycolytic
enzymes such as GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) [18] and neuronal-specific and non-
neuronal enolases [19]. These are multifunctional proteins
that are all expressed intracellularly but also on the
neuronal cell surface [20, 21]. They are involved in energy
metabolism, cell signaling, and synaptic neurotransmission
[22]. Although these AAbs can be present in normal
controls, they were present significantly more frequently
in the sera of retinopathy patients [23]. The biological
significance of anti-GADPH must be related to the roles of
GADPH as a multifunctional enzyme that is involved in
apoptosis, oxidative stress, activation of transcription,
membrane fusion, and vesicle transport. GADPH is a
cytosolic protein but can translocate to the nucleus in
apoptotic processes. Interestingly, GADPH is present in
large quantities in rod outer segments playing a role in the
production of energy for these active cells [21]. Therefore,
neuronal death induced during glycolysis inhibition
involves calcium influx through NMDA receptors and
calcium release from intracellular ER stores [17, 24].
Uncontrolled increases in intracellular calcium lets to
apoptotic cell death. It has been suggested that GADPH
plays a pathogenic role in human age-related neurodegen-
erative diseases, including Huntington's disease, Parkin-
son's disease, and Alzheimer's disease [25]. Neuronal
damage related to aging and chronic neurodegenerative
diseases has been suggested to be associated with
decreased glucose metabolism due to AAb action [24,
26]. Such possibility exists because GADPH is a strong
antigenic protein, especially during infections, which
leads to elucidation of anti-GADPH AAbs [22]a n d
similarity in the amino acid sequence of Streptococcal
and human proteins explains a cross-reactive immune
response against this protein [27]. Likewise, enolase and
aldolase are also expressed on Streptococcal pyogenes and
they too show significant identity between Streptococcal
and human neuronal glycolytic enzymes (apart from
aldolase C) [28].
Only a few of our patients have AAbs targeting the
astrocytic water channel protein, AQP4. Anti-AQP4 AAbs
has been found in a high percentage (~75%) of neuro-
myelitis optica patients (NMO-IgG), usually identified by
immunofluorescence only [13], suggesting the importance
of conformational epitopes, but also linear epitopes were
later recognized in denatured protein [29]. The recognition
of linear epitopes could explain the immunoreactivity
discordances observed for some serum samples, which
tested positive by immunocytochemistry but were negative
by WB, and vice versa. NMO is a rare inflammatory
demyelinating disease that selectively affects optic nerves
and spinal cord, usually not seen in multiple sclerosis (MS)
and other demyelinating syndromes of the CNS [30]. AAbs
against AQP4, which is expressed in astrocytic endfeet at
the blood brain barrier, are believed to induce damage to
astrocytes [31]. The close contact of AAbs/AQP4 positive
processes with oligodendrocytes and myelin tracts suggest
that a bystander effect of AAbs-damaged astrocytes on
oligodendrocytes might occur in the nervous tissues
affected by autoimmune optic neuropathy.
Optic neuritis associated with anti-AQP4-Ab affected
only females who had bilateral eye involvement, and all
had severe visual impairment in the acute phase and
delayed partial visual recovery [32]. Our patients with
serum anti-AQP4 were male. Similar to our patients, NMO
patients showed a predominant positive anti-MOG response
J Ophthal Inflamm Infect (2011) 1:111–121 119and anti-MBPAAbs. There are some clinical features that
overlap between autoimmune optic neuropathy and NMO
[6]. Despite the limited number of samples, presence of
such AAbs suggests a predominantly widespread acute
immune activation, including a strong B-cell response [30].
However, the role of anti-AQP4 AAbs in neuro-retinopathy
is not clear.
AAbs against CRMP5 were reported in paraneoplastic
syndrome patients with optic neuropathy and retinopathy
associated with the presence of vitreous and intrathecal
cells [12]. The neurological syndromes associated with
CRMP5 antibodies are very diverse (much like those
associated with anti-Hu antibodies) and include peripheral
neuropathy, limbic encephalitis, ataxia, as well as paraneo-
plastic chorea or optic neuritis [33]. Because anti-CRMP5
AAbs were found in almost 80% seropositive patients with
lung cancer, CRMP5 has become an established biomarker
for lung cancer-related paraneoplastic syndromes [33–35].
However, our CRMP5-seropositive patients did not have
cancer at the time of testing.
In summary, our research identified novel AAbs
specific against the optic nerve antigens unknown before
in autoimmune neuro-retinopathy, suggesting the autoim-
mune nature of the syndrome. Indirect evidence, coming
from clinical, functional, and imaging observations and
immunology strongly suggest that these AAbs may play
a direct role in the disease process. However, direct proof
of the pathogenic potential of these anti-optic nerve
antibodies is needed. If pathogenic, AAbs binding to
proteins in optic nerve neurons may lead to disruption of
protein function apoptosis of cells, as well as inhibiting
enzymes that preserve neuronal glycolytic activity and
neuronal integrity. Some of the neuronal antigens present
in these patients coincide with molecular targets in other
entities, such as NMO and other recognized paraneo-
plastic syndromes. These AAbs likely cause additional
visual loss via an optic nerve-related component in
autoimmune retinopathies that had been thus far under-
appreciated and underestimated in its frequency, and may
offer additional treatment targets for patients with
autoimmune neuro-retinopathies.
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